Qiagen N.V. (QGEN)
After hours:
| Previous close | 43.58 |
| Open | 43.67 |
| Bid | 42.99 x 1800 |
| Ask | 44.16 x 900 |
| Day's range | 43.58 - 44.03 |
| 52-week range | 34.74 - 47.70 |
| Volume | |
| Avg. volume | 1,006,785 |
| Market cap | 9.675B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 28.69 |
| EPS (TTM) | 1.52 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | 1.28 (2.94%) |
| Ex-dividend date | 30 Jan 2024 |
| 1y target est | 50.18 |
GlobeNewswireQIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics
Collaboration aims to create novel digital PCR assay to improve successful results in DNA analysis from human samples for use in forensics and human identification // DNA quantification enables law enforcement and forensic researchers to analyze a broader range of evidence more quickly, accurately and reliably // Collaboration strengthens QIAGEN’s leading position in human identification and forensicsVenlo, the Netherlands, and Washington, D.C., May 07, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGE
ZacksInternational Markets and Qiagen (QGEN): A Deep Dive for Investors
Review Qiagen's (QGEN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
GlobeNewswireQIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inherited disease applications
QCI Secondary Analysis a cloud-based software directly integrated with QCI Interpret, enabling high-throughput secondary analysis of clinical next-generation sequencing data // New software advances precision medicine by enabling smaller and decentralized labs to adopt NGS testing with efficiency, consistency and confidence // Combination of QCI Secondary Analysis and QCI Interpret provide a secure and compliant environment for trusted and scalable bioinformatics workflows for oncology and inher
